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Background
Lynch syndrome (LS) is responsible for around 2-3% of
all colorectal cancers [1]. Germline mutations within
one of four mismatch repair (MMR) genes, MLH1,
MSH2, MSH6, or PMS2, cause an increased risk in col-
orectal, endometrial, urinary tract, and other cancers.
Tumor screening, by microsatellite instability (MSI) and
immunohistochemistry (IHC) analysis, can be utilized
prior to mutation analysis in order to streamline the
testing process [2]. The following describes the use of
MSI and IHC to aid in the clinical interpretation of a
novel MMR mutation of uncertain significance and the
direct impact on cancer detection.
Materials and methods/results
Family X presented to our cancer genetics clinic with a
previously identified MSH2 MMR gene variant of uncer-
tain significance, 1227del12, detected in Sib 1, who was
diagnosed with synchronous colon cancers at age 53.
This mutation is an in-frame deletion of four amino
acids (Gln, Gly, Ile, Asn) in exon 7, which is located in
an alpha-helix turn of the protein. Sib 2 had a bladder
cancer at 56 years, and Sib 3 had a ureter cancer at
62 years. Sibs 2 and 3 were tested by standard DNA
sequencing for the specific VUS [6]. All three Sibs carry
the MSH2 1227del12 mutation. This mutation has not
been previously reported in the literature; hence clinical
interpretation of this VUS was limited. For this reason,
coordination of MSI and IHC was pursued for the three
Sibs’ tumors. MSI was high for Sibs 2 and 3 and unable
to be performed on Sib 1. All three Sibs’ tumors showed
concurrent loss of MSH2 and MSH6 by IHC.
Conclusions
This IHC pattern is suspicious of an underlying germline
mutation within the MSH2 gene [4,5]. In addition, both
of the tested tumors were MSI-high. Given these results,
and a significant family history, Family X was clinically
diagnosed with LS, with the MSH2 VUS as the likely
cause. Relatives with the VUS were informed to follow
LS management recommendations, and those without
the VUS should undergo high risk screening [2,3]. Sib 2
then underwent a colonoscopy one year from a previous
unremarkable colonoscopy, and a Stage I, 1.2 cm proxi-
mal colon adenocarcinoma with focal mucin production
was detected.
This case illustrates the benefit of tumor screening and
genetic professional expertise in the clinical interpreta-
tion of a MMR VUS as it applies to clinical diagnosis,
early detection and management of high risk families.
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